Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up from the 2-year DESTINATION study.
Christopher E BrightlingMarco CaminatiJean-Pierre LlanosScott CaveneyAles KotalikJanet M GriffithsAnna LundahlElliot IsraelIan D PavordMichael E WechslerCeleste PorsbjergJonathan CorrenMonika GołąbekNeil MartinSandhia PonnarambilPublished in: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology (2024)
ClinicalTrials.gov Identifier: NCT03706079.
Keyphrases